Evidence map›Paper›PMID 38867692›Full record

ArticleBioinformatics (Oxford, England)2024

HELM-GPT: de novo macrocyclic peptide design using generative pre-trained transformer.

Xiaopeng Xu, Chencheng Xu, Wenjia He, Lesong Wei, Haoyang Li, Juexiao Zhou, Ruochi Zhang, Yu Wang, Yuanpeng Xiong, Xin Gao

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. HELM-BERT: Topology-Aware Representations for Chemically Modified Peptides.Journal of chemical information and modeling · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. PepTune:ArXiv · 2025
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaopeng XuComputer Science Program, Computer, Electrical and Mathematical Science and Engineering (CEMSE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Makkah, Kingdom of Saudi Arabia.ORCID 0000-0003-2414-7851
Chencheng XuComputer Science Program, Computer, Electrical and Mathematical Science and Engineering (CEMSE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Makkah, Kingdom of Saudi Arabia.
Wenjia HeComputer Science Program, Computer, Electrical and Mathematical Science and Engineering (CEMSE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Makkah, Kingdom of Saudi Arabia.
Lesong WeiComputer Science Program, Computer, Electrical and Mathematical Science and Engineering (CEMSE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Makkah, Kingdom of Saudi Arabia.
Haoyang LiComputer Science Program, Computer, Electrical and Mathematical Science and Engineering (CEMSE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Makkah, Kingdom of Saudi Arabia.ORCID 0000-0003-3164-8240
Juexiao ZhouComputer Science Program, Computer, Electrical and Mathematical Science and Engineering (CEMSE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Makkah, Kingdom of Saudi Arabia.ORCID 0000-0002-6739-6236
Ruochi ZhangSyneron Technology, Guangzhou 510000, China.
Yu WangSyneron Technology, Guangzhou 510000, China.
Yuanpeng XiongSyneron Technology, Guangzhou 510000, China.
Xin GaoComputer Science Program, Computer, Electrical and Mathematical Science and Engineering (CEMSE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Makkah, Kingdom of Saudi Arabia.ORCID 0000-0002-7108-3574

Funding

King Abdullah University of Science and Technology URF/1/4352-01-01
6 · The paper itself

Abstract

motivationMacrocyclic peptides hold great promise as therapeutics targeting intracellular proteins. This stems from their remarkable ability to bind flat protein surfaces with high affinity and specificity while potentially traversing the cell membrane. Research has already explored their use in developing inhibitors for intracellular proteins, such as KRAS, a well-known driver in various cancers. However, computational approaches for de novo macrocyclic peptide design remain largely unexplored.

resultsHere, we introduce HELM-GPT, a novel method that combines the strength of the hierarchical editing language for macromolecules (HELM) representation and generative pre-trained transformer (GPT) for de novo macrocyclic peptide design. Through reinforcement learning (RL), our experiments demonstrate that HELM-GPT has the ability to generate valid macrocyclic peptides and optimize their properties. Furthermore, we introduce a contrastive preference loss during the RL process, further enhanced the optimization performance. Finally, to co-optimize peptide permeability and KRAS binding affinity, we propose a step-by-step optimization strategy, demonstrating its effectiveness in generating molecules fulfilling both criteria. In conclusion, the HELM-GPT method can be used to identify novel macrocyclic peptides to target intracellular proteins. AVAILABILITY AND IMPLEMENTATION: The code and data of HELM-GPT are freely available on GitHub (https://github.com/charlesxu90/helm-gpt).

Indexed as

Peptides, CyclicAlgorithmsComputational BiologyDrug DesignHumansPeptidesSoftwarePeptidesPeptides, Cyclic

Identifiers

PMID38867692
PMCPMC11256930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.